{
	"kja6j9j2Text": "F<span class=\"_ _c\"></span>agi<span class=\"_ _c\"></span>oli<span class=\"_ _2\"></span>ni A et a<span class=\"_ _2\"></span>l. 2<span class=\"_ _2\"></span>0<span class=\"_ _c\"></span>21<span class=\"fs1 v1\">1</span>",
	"kja6j9j3Text": "An inter<span class=\"_ _0\"></span>ventional, 8-week<span class=\"_ _0\"></span>, open-<span class=\"_ _0\"></span>label, flexible-<span class=\"_ _0\"></span>dose (<span class=\"_ _c\"></span>1<span class=\"_ _c\"></span>0<span class=\"_ _0\"></span>-2<span class=\"_ _2\"></span>0 mg<span class=\"_ _2\"></span>) s<span class=\"_ _0\"></span>tudy of<span class=\"_ _0\"></span> Brintellix® <br>on emotional blunting in major depressi<span class=\"_ _0\"></span>ve disorder (<span class=\"_ _2\"></span>MDD<span class=\"_ _c\"></span>)<span class=\"_ _0\"></span> patients w<span class=\"_ _0\"></span>ith par<span class=\"_ _0\"></span>tial<span class=\"_ _0\"></span> <br><span class=\"ls64 ws97\">response to SSRI/SNRI treatment.</span>",
	"kja6j9j4Text": "Study objective: <span class=\"ff3\">Assess the efficacy of Brintellix® on emotional blunting in patients <br>with partial r<span class=\"_ _2\"></span>esponse to current tr<span class=\"_ _2\"></span>eatment of SSRIs/SNRIs.</span>",
	"kja6j9j5Text": "Back",
	"kja6j9j6Text": "Key inclusion criteria",
	"kja6j9j7Text": "P<span class=\"_ _c\"></span>atients 18-65 years of<span class=\"_ _0\"></span> age with a <br>primary diagnosis of<span class=\"_ _0\"></span> MDD per DSM-5 <br>and a current depressive episode of &lt;12<span class=\"_ _0\"></span> <br>months’ durations,<span class=\"_ _2\"></span> with partial response <br>to an SSRI/SNRI monotherapy at appr<span class=\"_ _2\"></span>oved <br>doses for ≥6 weeks prior to the screening <br>visit. P<span class=\"_ _c\"></span>atients have MADRS total score <br>&gt;21and &lt;29 (depression severity) and ODQ <br>total score ≥50 at baseline, and subjective <br>confirmation of emotional blunting by <br>standardised screening question.",
	"kja6j9j8Text": "Clinical and safety assessments <br>wereconducted at baseline (except <br>for the CGI-I) and at W1,<span class=\"_ _2\"></span> W4 and W8.",
	"kja6j9j9Text": "Primary outcome: <span class=\"ff3 ls62 wsa7\">Emotio<span class=\"_ _2\"></span>nal blu<span class=\"_ _2\"></span>nting assessed by mean cha<span class=\"_ _2\"></span>nge <br><span class=\"ls36 wsb\">from we<span class=\"_ _2\"></span>ek 0 to w<span class=\"_ _2\"></span>eek 8 in OD<span class=\"_ _2\"></span>Q total sc<span class=\"_ _2\"></span>ore us<span class=\"_ _2\"></span>ing a m<span class=\"_ _2\"></span>ixe<span class=\"_ _2\"></span>d model f<span class=\"_ _2\"></span>or <br>repe<span class=\"_ _2\"></span>ated m<span class=\"_ _2\"></span>easu<span class=\"_ _2\"></span>rem<span class=\"_ _2\"></span>ents (MM<span class=\"_ _2\"></span>RM) i<span class=\"_ _c\"></span>ncludi<span class=\"_ _2\"></span>ng site a<span class=\"_ _2\"></span>nd wee<span class=\"_ _2\"></span>k as fix<span class=\"_ _2\"></span>ed <br><span class=\"ls38 ws7e\">ef<span class=\"_ _0\"></span>fec<span class=\"_ _0\"></span>t<span class=\"_ _0\"></span>s,<span class=\"_ _0\"></span> the baseline score as a<span class=\"_ _0\"></span> continuous covariate and the baselince<span class=\"_ _0\"></span> <br><span class=\"ls47 ws6d\">score<span class=\"_ _0\"></span>-by-<span class=\"_ _0\"></span>week inte<span class=\"_ _0\"></span>rac<span class=\"_ _0\"></span>t<span class=\"_ _0\"></span>ion.</span></span></span></span>",
	"kja6j9jaText": "MADRS, Mont<span class=\"_ _2\"></span>gomery-Åsberg Deoressio<span class=\"_ _2\"></span>n Rating Scale<span class=\"_ _c\"></span>; ODQ, Ox<span class=\"_ _0\"></span>ford Dep<span class=\"_ _2\"></span>ression Question<span class=\"_ _2\"></span>naire<span class=\"_ _c\"></span>; MEI, Motivation a<span class=\"_ _2\"></span>nd Energy I<span class=\"_ _2\"></span>nven<span class=\"_ _2\"></span>tory; SDS, Sheeh<span class=\"_ _2\"></span>an Disabi<span class=\"_ _2\"></span>lity Scale; D<span class=\"_ _2\"></span>SST<span class=\"_ _c\"></span>, <br><span class=\"ls65 wsb6\">Digi<span class=\"_ _0\"></span>t Symbol Subs<span class=\"_ _0\"></span>tit<span class=\"_ _0\"></span>ution Test.</span>",
	"kja6j9jbText": "Secondary ou<span class=\"_ _0\"></span>tcomes: <span class=\"ff3 ls48 wsb7\">Measures of depress<span class=\"_ _0\"></span>ive <br><span class=\"ls4a ws83\">sy<span class=\"_ _0\"></span>mptoms (MADRS), motivation<span class=\"_ _0\"></span> and energy (MEI), <br><span class=\"ls38 ws7e\">psychosocial func<span class=\"_ _0\"></span>t<span class=\"_ _0\"></span>ioning (<span class=\"_ _c\"></span>SDS), and cognitive <br><span class=\"ls66 wsb8\">per<span class=\"_ _1\"></span>formance (DSST).</span></span></span></span>",
	"kja6j9jcText": "Part<span class=\"_ _0\"></span>ial responders",
	"kja6j9jdText": "with MDD who",
	"kja6j9jeText": "want to s<span class=\"_ _0\"></span>witch",
	"kja6j9jfText": "and ans<span class=\"_ _0\"></span>wered yes",
	"kja6j9jgText": "to the<span class=\"_ _0\"></span> screening",
	"kja6j9jhText": "ques<span class=\"_ _0\"></span>tion:",
	"kja6j9jiText": " • MADRS ≥22",
	"kja6j9jjText": "an<span class=\"_ _0\"></span>d ≤<span class=\"_ _0\"></span>28",
	"kja6j9jkText": " • ODQ ≥50",
	"kja6j9jlText": "Open-<span class=\"_ _0\"></span>label per<span class=\"_ _0\"></span>iod",
	"kja6j9jmText": "Baseline",
	"kja6j9jnText": "4 clin<span class=\"_ _2\"></span>ic visits",
	"kja6j9joText": "Wee<span class=\"_ _0\"></span>k<span class=\"_\"> </span><span class=\"ls6d wsad\">-6<span class=\"_\"> </span><span class=\"ls5 wsae\">0<span class=\"_\"> </span>1<span class=\"_ _2a\"> </span>4<span class=\"_ _2b\"> </span>8<span class=\"_ _2c\"> </span><span class=\"ls6e\">12</span></span></span>",
	"kja6j9jpText": "Safet<span class=\"_ _0\"></span>y",
	"kja6j9jqText": "follow-<span class=\"_ _0\"></span>up",
	"kja6j9jrText": "Safet<span class=\"_ _0\"></span>y c<span class=\"_ _0\"></span>linic visi<span class=\"_ _0\"></span>t ",
	"kja6j9jsText": "(<span class=\"_ _2\"></span>may be telephone ",
	"kja6j9jtText": "contac<span class=\"_ _0\"></span>t)",
	"kja6j9juText": "Previous",
	"kja6j9jvText": "SSRI / SNR<span class=\"_ _0\"></span>I",
	"kja6j9jwText": "treatme<span class=\"_ _2\"></span>nt",
	"kja6j9jxText": "Brintellix®",
	"kja6j9jyText": "10<span class=\"_ _0\"></span> m<span class=\"_ _0\"></span>g<span class=\"_ _1\"></span>/d<span class=\"_ _0\"></span>a<span class=\"_ _0\"></span>y",
	"kja6j9jzText": "(n<span class=\"_ _0\"></span>=<span class=\"_ _0\"></span>15<span class=\"_ _0\"></span>0)",
	"kja6j9k0Text": "Brintellix®",
	"kja6j9k1Text": "Can remain",
	"kja6j9k2Text": "10<span class=\"_ _0\"></span> m<span class=\"_ _0\"></span>g<span class=\"_ _1\"></span>/d<span class=\"_ _0\"></span>a<span class=\"_ _0\"></span>y",
	"kja6j9k3Text": "or increase to",
	"kja6j9k4Text": "20 mg/<span class=\"_ _c\"></span>day (n=<span class=\"_ _c\"></span>1<span class=\"_ _2\"></span>43<span class=\"_ _2\"></span>)",
	"Brintellix_88a56dc2b6": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_8841f1e5ac": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Fagiolini A et al. J Affect Disord 2021;283:472-479.</div>"
}
